Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 35Carcinoma, Hepatocellular 17Neoplasm Metastasis 15Prostatic Neoplasms 13Neoplasms 9Neuroendocrine Tumors 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 6Brain Neoplasms 6Sarcoma, Ewing 5Sarcoma 5Osteosarcoma 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Transitional Cell 5Recurrence 4Pancreatic Neoplasms 4Multiple Myeloma 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Pheochromocytoma 2Paraganglioma 2Neurofibroma, Plexiform 2Melanoma 2

Interventions

pembrolizumab 3atezolizumab 2Sugammadex 2Saline Solution 2Paclitaxel 2Neostigmine 2Gemcitabine 2Cetuximab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1poly ICLC 1lenvatinib 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1delta 24-sterol reductase 1daratumumab 1cabozantinib 1abemaciclib 1Zoledronic Acid 1Water 1Valproic Acid 1Urinary Diversion 1Ultrasonography 1Trastuzumab 1Tomography, Optical Coherence 1Tissue Banks 1Therapeutics 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urologic Neoplasms × cabozantinib × Clear all
NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡